Mather, Kieren J.

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy

Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 41

Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial

Knowler, W. C., Doherty, L., Edelstein, S. L., Bennett, P. H., Dabelea, D., Hoskin, M., Kahn, S. E., Kalyani, R. R., Kim, C., Pi-Sunyer, F. X., et al. (2025) · The Lancet Diabetes & Endocrinology

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 39

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial

Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 39

Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants

Hivert, M.-F., Christophi, C. A., Franks, P. W., Jablonski, K. A., Ehrmann, D. A., Kahn, S. E., Horton, E. S., Pollin, T. I., Mather, K. J., Perreault, L., et al. (2016) · Diabetes

Genetic Associations and EpidemiologyDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 38

Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes

Xiang, A. H., Trigo, E., Martinez, M., Katkhouda, N., Beale, E., Wang, X., Wu, J., Chow, T., Montgomery, C., Nayak, K. S., et al. (2018) · Diabetes Care

Bariatric Surgery and OutcomesDiabetes Treatment and Management

Cited by 37

Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test

Mather, K. J., Mari, A., Heise, T., DeVries, J. H., Hua, M., Urva, S., Coskun, T., Haupt, A., Heine, R. J., Pratt, E., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 35

Prevalence of microvascular and macrovascular disease in the glycemia reduction approaches in diabetes - a comparative effectiveness (GRADE) study cohort

Mather, K. J., Bebu, I., Baker, C., Cohen, R. M., Crandall, J. P., DeSouza, C., Green, J. B., Kirkman, M. S., Krause-Steinrauf, H., Larkin, M., et al. (2020) · Diabetes Research and Clinical Practice

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 34

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

KNOP, F. K., URVA, S., RETTIGANTI, M., BENSON, C., ROELL, W., MATHER, K. J., HAUPT, A., & PRATT, E. J. (2023) · Diabetes

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 29

The Diabetes Prevention Program and Its Outcomes Study: NIDDK’s Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact

Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., DPP Research Group, Bray, G. A., Gadde, K. M., Culbert, I. W., Arceneaux, J., et al. (2025) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 29

Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 26

Comparison of β-cell function between overweight/obese adults and adolescents across the spectrum of glycemia

Chen, M. E., Chandramouli, A. G., Considine, R. V., Hannon, T. S., & Mather, K. J. (2018) · Diabetes Care

Pancreatic function and diabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 26

Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program

Goldberg, R. B., Temprosa, M., Mele, L., Orchard, T., Mather, K., Bray, G., Horton, E., Kitabchi, A., Krakoff, J., Marcovina, S., et al. (2016) · Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 22